For STAT, Ed Silverman reports on growing concerns about the industry ties of the new nominee for FDA commissioner. “The nomination comes at a pivotal time for the FDA,” he writes. “The agency is under increasing pressure from drug companies and patients to approve more medicines faster than ever. Congress is considering legislation designed to accelerate innovation, although some critics say the effort threatens to lower safety standards for approving some products.”
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.